Previous 10 | Next 10 |
Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of concerned shareholders (the " Concerned Shareholders ") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE...
FSD Pharma (HUGE) announces that it has submitted an Investigational New Animal Drug Application ((IND)) to the U.S. FDA for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat gastrointestinal enteropathy in dogs.The proposed trial design is a...
The FDA has accepted the Investigational new Animal Drug application for review The proposed trial is expected to be conducted at 5-10 sites in USA and will enroll up to 200 dogs Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on May 12, 2021 ...
Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on May 12, 2021 FSD Pharma Inc. (the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent international corporate governance analysis and ...
FSD Pharma (HUGE) appoints Nathan Coyle, the company's corporate controller as its interim CFO, following the departure of Donal Carroll, effective immediately.Mr. Coyle joined FSD Pharma Inc in 2020 as Corporate Controller and has 15 years of executive business experience as a...
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the " Company " or " FSD Pharma ") is pleased to announce the appointment of Nathan Coyle, the Company's Corporate Controller as its Interim Chief Financial Officer, following the departure of Donal Carroll, effective immediately. ...
Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - On Monday, April 26, 2021, the group of concerned shareholders (the " Concerned Shareholders ") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the " Company " or " FSD ") filed and mailed an information circular and gold proxy t...
Management director nominees bring superior experience and expertise to drive positive growth, represent ALL shareholders interests and create value for ALL shareholders. FSD's COVID-19 FDA trials gaining momentum. Management actively pursuing multi...
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting PR Newswire TORONTO , April 5, 2021 /PRNewswire/ - On Tuesday, March 30, 2021 , Anthony Durkacz , a founding director and member of the group of concerned sha...
- Proceedings intended to appeal elements of Ontario Commercial List decision and challenge dissidents over material conflicts of interest and disclosure deficiencies - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”)...
News, Short Squeeze, Breakout and More Instantly...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of finan...
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE...
2024-07-25 08:16:52 ET DENVER, Colo., Jul 25, 2024 ( 247marketnews.com )- Coca-Cola (NYSE: KO ) , FSD Pharma (NASDAQ: HUGE ), and Celsius Holdings, Inc. (NASDAQ: CELH ) Sometimes, there are some winning streaks that are so strong that even...